New drug-eluting stents very promising

December 5, 2017 by Berend Meijering, University of Twente

New-generation stents containing anti-vasoconstriction medication perform well. They are safe and efficient for most patients, over both the short term and the long term. According to Liefke van der Heijden, a trainee cardiologist at the Medisch Spectrum Twente hospital, future research into stents may focus on high-risk patients or those with complex lesions. She will be awarded a PhD by the University of Twente's Faculty of Behavioural, Management and Social Sciences (BMS) on Wednesday 6 December. Her doctoral thesis is titled Second-generation drug-eluting stents and beyond.

Drug-eluting (DES) have become an indispensable element in the treatment of constrictions. In many cases, keeping coronary arteries open by inserting small, drug-containing tubes is an alternative to major heart bypass surgery. The steady stream of new developments means that stents are progressively becoming safer and more effective. Second-generation stents are already outperforming the first generation devices. They are biocompatible, so there is less risk of an inflammatory reaction, of blood vessel constriction, and of potential new constrictions developing in the coronary artery. The ongoing development of stents has brought an added benefit – the platforms have become more flexible, which has made it much easier to position them. This is particularly useful in the treatment of coronary artery constrictions where the type and extent of the lesions involved makes it more difficult to position the stent.

Dr Van der Heijden's research focuses on second generation , and the more recent generations. Both short-term and long-term follow-up show excellent results in terms of safety and effectiveness. Her doctoral thesis also covers the latest research in this area. The stents that are currently under development include a category that is partially bioresorbable (biologically soluble) and another that is completely bioresorbable. The partially bioresorbable stents are already showing good short-term results. However, there is some debate concerning the safety of the first generation of fully bioresorbable stents. In theory, they are very promising but, as yet, nothing is known about their potential long-term benefits. Studies are needed to find out how their short-term results can be improved.

After stenting, some patients are at greater risk of an adverse outcome than others. These tend to be patients who have had previous bypass surgery, patients whose treatment involved small vessels, patients with highly calcified coronary and with a constriction at the point where a coronary artery branches. Certain stent properties could provide better clinical outcomes for these groups in particular. This University of Twente PhD candidate feels that, given the high risk of blood vessel constriction (or re-constriction), future research should ideally focus on this patient population in particular.

Explore further: New drug-eluting stents more effective

Related Stories

New drug-eluting stents more effective

July 15, 2014
Research conducted by University of Twente PhD candidate Kenneth Tandjung has shown that the new generation of drug-eluting stents, which is being used in coronary angioplasty to open narrowed coronary arteries, is safe and ...

Cardiologist warns against dissolvable stents in NEJM

April 6, 2017
In a New England Journal of Medicine (NEJM) editorial published last week, Debabrata Mukherjee, M.D., provides expert commentary on bioresorbable stents, an alternative to the traditional stents used in patients with cardiac ...

Results from the BIO-RESORT trial presented

October 31, 2016
Results of a large-scale, multicenter study found that treatment with two thin-strut drug-eluting stents were both non-inferior to a durable polymer drug-eluting stent and showed favorable clinical outcomes at one year in ...

Results of DUTCH PEERS (TWENTE II) trial reported

October 31, 2013
Results of the DUTCH PEERS (TWENTE II) clinical trial demonstrate comparable safety and efficacy of two third-generation permanent polymer-based drug-eluting stents with low rates of adverse clinical events and establish ...

Drug-eluting stents more benefit in saphenous vein graft

August 30, 2016
Drug-eluting stents had a clear advantage over bare metal stents in patients undergoing revascularisation of saphenous (leg) vein grafts, results of the BASKET-SAVAGE trial show.

EuroPCR issues statement on bioresorbable stent (BRS) technologies

May 22, 2017
Ongoing development of bioresorbable stent (BRS) technologies that are bioresorbed after achieving vessel expansion in percutaneous coronary intervention procedures is an important option to optimise outcomes in patients ...

Recommended for you

Physical activity necessary to maintain heart-healthy lifestyle

September 24, 2018
Exercise and physical activity are of vast global importance to prevent and control the increasing problem of heart disease and stroke, according to a review paper published today in the Journal of the American College of ...

Height may be risk factor for varicose veins, study finds

September 24, 2018
The taller you are, the more likely you are to develop varicose veins, according to a study led by Stanford University School of Medicine researchers that examined the genes of more than 400,000 people in search of clues ...

Prosthetic valve mismatches common in transcatheter valve replacement, ups risk of death

September 24, 2018
In the largest multi-institutional study to date, led by researchers from Penn Medicine, the team found that among patients who underwent a transcatheter aortic valve replacement (TAVR), a high number experienced severe and ...

Study reveals a promising alternative to corticosteroids in acute renal failure treatment

September 21, 2018
A protein produced by the human body appears to be a promising new drug candidate to treat conditions that lead to acute renal failure. This is shown by a study conducted at São Paulo State University (UNESP) in São José ...

Can a common heart condition cause sudden death?

September 20, 2018
About one person out of 500 has a heart condition known as hypertrophic cardiomyopathy (HCM). This condition causes thickening of the heart muscle and results in defects in the heart's electrical system. Under conditions ...

New drugs could reduce risk of heart disease when added to statins

September 20, 2018
New drugs that lower levels of triglycerides (a type of fat) in blood could further reduce the risk of heart attack when added to statins. These new drugs, which are in various stages of development, could also reduce blood ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.